Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Johns Hopkins Kimmel Cancer Center in Baltimore
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia.
PATIENT CHARACTERISTICS: ï¿½WBC count less than 50,000/mm^3 PRIOR CONCURRENT THERAPY: ï¿½See Disease Characteristics ï¿½No prior cytotoxic chemotherapy for the current diagnosis of ALL or any cancer diagnosed previously oSteroids* and intrathecal cytarabine for the current diagnosis of ALL allowed ï¿½Inhalational steroids are not considered as pretreatment See protocol for extensive disease stratification information
Drug: cyclophosphamide Drug: cytarabine Drug: dexamethasone Drug: doxorubicin hydrochloride Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: pegaspargase Drug: thioguanine Drug: vincristine sulfate
07/30/2015 09:39 AM